Zevra Therapeutics Amends 8-K Filing, Updates Event Date
Ticker: ZVRA · Form: 8-K/A · Filed: Feb 5, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, administrative, corporate-governance
TL;DR
**Zevra Therapeutics filed an 8-K/A to correct a date, no new news.**
AI Summary
Zevra Therapeutics, Inc. filed an 8-K/A on February 5, 2024, to amend its previous 8-K filing from November 20, 2023. This amendment, filed under the Securities Exchange Act of 1934, primarily updates the 'Date of Earliest Event Reported' to February 2, 2024, clarifying the effective date of certain information. For investors, this filing is a routine administrative update, indicating no new material financial or operational changes, but rather a correction to a previous disclosure, which is generally a neutral event.
Why It Matters
This filing is an administrative correction, not a new event. It clarifies the effective date of a previous report, which is important for accurate record-keeping but doesn't signal new financial or operational news for Zevra Therapeutics.
Risk Assessment
Risk Level: low — This filing is an administrative amendment to correct a date and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would recognize this as a routine administrative update with no immediate impact on the company's fundamentals or stock price. No action is typically warranted based solely on this type of filing.
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- November 20, 2023 (date) — the original 'Date of Earliest Event Reported' in the initial 8-K
- February 2, 2024 (date) — the updated 'Date of Earliest Event Reported' in the 8-K/A
- Delaware (company) — state of incorporation for Zevra Therapeutics, Inc.
- 001-36913 (company) — Commission File Number for Zevra Therapeutics, Inc.
- 20-5894398 (company) — IRS Employer Identification No. for Zevra Therapeutics, Inc.
- ZVRA (company) — trading symbol for Zevra Therapeutics, Inc.
- The Nasdaq Global Select Market (company) — exchange where Zevra Therapeutics, Inc. common stock is registered
FAQ
What is the primary purpose of Zevra Therapeutics, Inc.'s 8-K/A filing dated February 5, 2024?
The primary purpose of Zevra Therapeutics, Inc.'s 8-K/A filing is to amend its previous 8-K report and update the 'Date of Earliest Event Reported' from November 20, 2023, to February 2, 2024.
Under which section of the Securities Exchange Act of 1934 was this amendment filed?
This amendment was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Zevra Therapeutics, Inc.'s trading symbol and on which exchange is its common stock registered?
Zevra Therapeutics, Inc.'s trading symbol is ZVRA, and its common stock, with a $0.0001 par value per share, is registered on The Nasdaq Global Select Market.
What is the business address and phone number of Zevra Therapeutics, Inc. as stated in the filing?
The business address of Zevra Therapeutics, Inc. is 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747, and its telephone number is (321) 939-3416.
What was the former name of Zevra Therapeutics, Inc. and when did its name change?
Zevra Therapeutics, Inc. was formerly known as KEMPHARM, INC., with a name change date of May 30, 2013, and even earlier as KEMPHARM INC. with a name change date of May 7, 2008.
Filing Stats: 865 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2024-02-02 17:54:32
Key Financial Figures
- $0.0001 — ge on which registered Common Stock , $0.0001 par value per share ZVRA The Nasdaq G
Filing Documents
- zvra20240126_8ka.htm (8-K/A) — 34KB
- ex_621697.htm (EX-23.1) — 3KB
- ex_621158.htm (EX-99.3) — 383KB
- 0001437749-24-003003.txt ( ) — 587KB
- zvra-20231120.xsd (EX-101.SCH) — 3KB
- zvra-20231120_def.xml (EX-101.DEF) — 12KB
- zvra-20231120_lab.xml (EX-101.LAB) — 15KB
- zvra-20231120_pre.xml (EX-101.PRE) — 12KB
- zvra20240126_8ka_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Businesses or Funds Acquired. The historical audited financial statements of Acer Therapeutics Inc. as of December 31, 2022, and 2021 and for each of the years ended December 31, 2022, as well as the accompanying notes thereto and the related Report of Independent Registered Public Accounting Firm issued by BDO USA, LLP (n/k/a BDO USA, P.C.), dated March 27, 2023, ar e filed hereto as Exhibit 99.1 and incorporated herein by reference. The historical unaudited financial statements of Acer Therapeutics Inc. as of and for the nine months ended September 30, 2023, as well as the accompanying notes thereto, are filed hereto as Exhibit 99.2 and incorporated herein by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined statement of operations of the Company for the nine months ended September 30, 2023, and the unaudited pro forma condensed combined balance sheet of the Company as of the nine months ended September 30, 2023, and the notes related thereto, are filed as Exhibit 99.3 hereto and are incorporated herein by reference. The unaudited pro forma condensed combined financial information combines the Company's financial statements with Acer Therapeutics Inc.'s financial statements. (d) Exhibits Exhibit No. Description 23.1 Consent of BDO USA, P.C., Independent Registered Public Accounting Firm. 99.1 Financial Statements of Acer Therapeutics Inc. as of December 31, 2022 and 2021 and for each of the years in the period ended December 31, 2022 and Report of Independent Registered Public Accounting Firm (incorporated herein by reference to the Registrant's Registration Statement on Form S-4 as filed with the SEC on September 29, 2023). 99.2 Unaudited Financial Statements of Acer Therapeutics Inc. as of and for the nine months ended September 30, 2023 (incorporated herein by reference to Part I – Financial Information – Item 1. in the Acer Th
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc . Date: February 2, 2024 By: /s/ R. LaDuane Clifton R. LaDuane Clifton, CPA Chief Financial Officer, Secretary and Treasurer